PD-L1 & 4-1BB (2)

Reference the resources below for more information about the product/service or contact us today to learn more.

Strain Information

  • Catalog Number ASHU-200260
  • Model Name PD-L1 & 4-1BB (2)
  • Strain Name C57BL/6 - Cd274em1(hPD-L1)Tnfrsf9tm2(hTNFRSF9)/Asc
  • Mutation Type Humanized
  • GENE Synonyms Pd-L1, Cd274, 4-1BB, Cd137, CDw137, AA408498, AI325004, A930040I11Rik
  • Human Orthologs CD274, TNFRSF9
  • Emsamble ID ENSMUSG00000016496, ENSMUSG00000028965
  • MGI ID 1926446, 104879
  • NCBI ID 60533, 18566
  • Background C57BL/6
  • Coat Color Black
  • Mutation Type Humanized
Animal Request Form Inquire
Catalog # :
Availability :
  • Description
  • Research Application
  • Related Products

Humanized Strategy

PD-L1 Humanization Strategy


4-1BB (2) Humanization Strategy


Validation Data: PD-L1


Figure 1. Expression of PD-L1 in the spleen lymphocytes collected from homozygous humanized PD-L1 mice and wild-type mice is detected by FACS. The results showed that the expression of human PD-L1 can be detected in both T cells and B cells collected from the spleen of homozygous humanized PD-L1 mice. (Data in partnership with collaborators)


Figure 2. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized PD-L1 mice. Homozygous humanized PD-L1 mice were inoculated with MC38 colon cancer cells (expressing human PDL1 rather than murine PD-L1). After the tumors grew to 100 mm3, the animals were randomly assigned into a control group and a treatment group (n=5). The results showed: The antibodies targeting human PD-L1 were associated with a very significant anti-tumor effect (TGI: tumor growth inhibition, p < 0.001), demonstrating that the humanized PD-L1 mice are a good in vivo model for validating the efficacy of antibodies targeting human PD-L1.

Validation Data: 4-1BB (2)


Figure 3. Expression of humanized CD137(4-1BB) in the activated spleen lymphocytes of heterozygous humanized 4-1BB mice is detected by FACS. 

The spleen lymphocytes of heterozygous humanized 4-1BB mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. The expression of humanized 4-1BB was detected by FACS. The results showed that the active expression of humanized 4-1BB can be detected in both activated CD4+ and CD8+ T lymphocytes collected from heterozygous humanized 4-1BB mice. (Data in partnership with collaborators)


Figure 4.  Analysis of human 4-1BB (CD137) expression in the spleen by FACS. The homozygous KI mouse expresses human 4-1BB on the CD8+ T cells.


Figure 5.In vivo validation of humanized 4-1BB mice. Humanized 4-1BB mice were inoculated with MC38 colon cancer cells, and were randomly assigned into different groups (n=6) when the tumors grew to a volume of 100 mm3. Human-specific, 4-1BB antibody (Urelumab or Utomilumab) was given every three days (Q3D) for two weeks (Data in partnership with collaborators).  

Tumor research, Immunotherapy, drug screening